In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on Bluebird Bio (BLUE). The company’s shares opened today at $123.61.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 12.7% and a 61.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $163 average price target, representing a 31.9% upside. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $195 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $196.20 and a one-year low of $87.49. Currently, Bluebird Bio has an average volume of 462K.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is neutral on the stock. Last month, Jason Cole, the Chief Operating and of BLUE bought 562 shares for a total of $28,387.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
